Tyra Biosciences prices $126M stock offering

Tyra Biosciences, Inc. entered into an agreement to issue and sell 4,000,000 shares of common stock to a large investment management firm in a block transaction.

Rhea-AI Filing Summary

Tyra Biosciences, Inc. entered into an agreement to issue and sell 4,000,000 shares of common stock to a large investment management firm in a block transaction. The shares are priced at $31.50 per share, and Tyra Biosciences expects to receive $126.0 million in gross proceeds upon settlement, before fees and other expenses.

The transaction is being carried out under the company’s existing “at-the-market” offering program, which is registered on Form S-3 under the Securities Act of 1933. The terms of this program are described in a sales agreement prospectus dated May 16, 2025, with related documents available on the SEC’s website.

Insights

Equity capital markets analyst

Tyra Biosciences raises $126M via an at-the-market block stock sale.

Tyra Biosciences agreed to sell 4,000,000 common shares at $31.50 per share to a large investment management firm. This block trade under its at-the-market program is expected to generate $126.0 million in gross proceeds before fees and expenses.

The transaction uses an existing Form S-3 shelf registration and a sales agreement prospectus dated May 16, 2025, which streamlines issuance mechanics. The filing does not specify how the company plans to deploy these funds, so the ultimate business impact depends on future capital allocation decisions.

Investors can locate the registration statement, prospectus supplement, and accompanying prospectus on the SEC’s website to understand the broader at-the-market program framework, including any ongoing capacity for additional issuances beyond this $126.0 million block sale.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

What equity financing did Tyra Biosciences (TYRA) announce?

Tyra Biosciences agreed to sell 4,000,000 common shares to a large investment management firm. The shares are priced at $31.50 each, creating expected $126.0 million in gross proceeds before deducting fees and other expenses payable by the company.

At what price is Tyra Biosciences (TYRA) issuing new shares?

Tyra Biosciences is issuing 4,000,000 shares of common stock at a purchase price of $31.50 per share. This pricing results in expected $126.0 million in gross proceeds upon settlement, prior to fees and other expenses owed by the company.

How much capital will Tyra Biosciences (TYRA) receive from the stock sale?

Tyra Biosciences expects to receive $126.0 million in gross proceeds from selling 4,000,000 common shares. This figure reflects the agreed purchase price of $31.50 per share and is stated before deducting any fees or other expenses payable by the company.

What structure is Tyra Biosciences (TYRA) using for this equity issuance?

Tyra Biosciences is issuing the shares as a block transaction under its existing “at-the-market” offering program. That program is registered on Form S-3 under the Securities Act of 1933 and is governed by a sales agreement prospectus dated May 16, 2025.

Under which registration has Tyra Biosciences (TYRA) registered this offering?

The stock sale is conducted under Tyra Biosciences’ Form S-3 shelf registration statement, file number 333-287086, filed May 8, 2025. The related prospectus supplement and accompanying prospectus are accessible through the SEC’s website at www.sec.gov for further details.

Who is buying the newly issued Tyra Biosciences (TYRA) shares?

Tyra Biosciences agreed to issue and sell the 4,000,000 common shares to a large investment management firm. The transaction is structured as a block trade within the company’s existing at-the-market equity offering program registered under the Securities Act of 1933.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 05:18 PM Learn about SEC filing dates

false 0001863127 0001863127 2026-03-04 2026-03-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 04, 2026

Tyra Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-40800		83-1476348
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
2656 State Street
Carlsbad, California				92008
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (619) 728-4760

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		TYRA		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On March 4, 2026, Tyra Biosciences, Inc. (the “Company”) agreed to issue and sell 4,000,000 shares of common stock to a large investment management firm at a purchase price of $31.50 per share. The Company expects to receive $126.0 million in gross proceeds upon settlement, before deducting fees and other expenses payable by it.

The shares of common stock are being issued as a block transaction under the Company’s “at-the-market” offering program, which has been registered under the Securities Act of 1933 pursuant to a registration statement on Form S-3 (File No. 333-287086) filed with the Securities and Exchange Commission on May 8, 2025. The terms of the Company’s “at-the-market” offering program are described in the sales agreement prospectus, dated May 16, 2025. Copies of the registration statement, prospectus supplement and accompanying prospectus can be accessed through the Securities and Exchange Commission’s website at www.sec.gov.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

						TYRA BIOSCIENCES, INC.
Date: March 4, 2026				By:		/s/ Alan Fuhrman
						Alan Fuhrman
						Chief Financial Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB